Cardiovascular Pharmacology: Open Access

Acanfora C

Publications

• Review Article
  Direct Oral Anticoagulants, Bleeding Risk in Patients with Atrial Fibrillation, CHADS2 ≥ 3 or HAS-BLED ≥ 3
  Author(s): Acanfora D, Casucci G, Ciccone MC, Scicchitano P, Montefusco G, Lanzillo A, Acanfora C and Lanzillo BAcanfora D, Casucci G, Ciccone MC, Scicchitano P, Montefusco G, Lanzillo A, Acanfora C and Lanzillo B
  
  To evaluated the safety of direct oral anticoagulants as compared to warfarin in a subgroup of patients with atrial fibrillation (AF) who should undergo antithrombotic therapy such as patients with CHADS2 score ≥ 3. We evaluated the incidence of major bleeding in patients with AF and CHADS2 score ≥ 3 in the RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE studies. Also we evaluated the incidence of major bleeding in patients at higher hemorrhagic risk (HAS-BLED ≥ 3). Data was derived from eleven studies whose results came from the pivotal trials. Our aim was to propose a critical debate on the collected data. There were some striking differences between the 4 considered studies: a high percentage of bleeding in the subpopulation at high risk of stroke or systemic embolism or at high risk of bleeding. Some studies reported a higher frequency of bleeding in the warfarin arm. T.. View More»
  DOI: 10.4172/2329-6607.1000240

  Abstract PDF